FDA changes metformin guidelines

The FDA is revising its warnings about the risks of metformin in those with chronic kidney disease (CKD) -- see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494829.htm , or http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf​ for more info), "requiring manufacturers to revise labeling of metformin-containing drugs to indicate that these products may be safely used in patients with mild to moderate renal impairment". although i have sent out many blogs on metformin, i think it is such an important drug that i am sending out this as yet another one. the new FDA labeling recommendations:

--before starting metformin, check eGFR
--metformin is contraindicated in patients with an eGFR <30
--starting metformin in those with eGFR 30-45 is NOT recommended
--obtain eGFR at least annually, more frequently if increased risk of renal dysfunction (eg, elderly)
--if a patient is on metformin and the eGFR falls to below 45, assess the benefits and risks of continuing treatment [not further defined..]. discontinue metformin if eGFR falls to <30
--discontinue metformin at time, or before, an iodinated contrast imaging procedure in patients with eGFR 30-60, in those with a history of liver disease, alcoholism, or heart failure; and in those getting intra-arterial iodinated contrast. re-evaluate eGFR 48 hours after the procedure and restart metformin if renal function is stable. 

so, a few comments:
--it's about time.....   See a few of my many blogs below on metformin, which highlight its incredible importance in diabetics, its current use in the US in those with CKD despite prior strict precautions, its general use in Europe where regulatory agencies suggest using it with decreasing doses depending on the degree of CKD, and even a blog which refers to its effects on the microbiome (and suggesting that these effects may be extremely important in metformin's mechanism of action). 
--one concern with the above is that they suggest following eGFR more closely in the elderly.  this is difficult, since (at least in our lab), eGFR is not reported in those >70: “eGFR values may not be accurate on patients greater than 70 years of age and are not calculated". my approach is to continue with metformin in the elderly (even those in their 90s) if their creatinine seems "reasonable" -- not easy to quantitate, but if their creatinine is below 1.5 or so, and throwing in some gestalt about their likely muscle mass...  But, bottom line, i have been doing this for years on a pretty large patient base and without any adverse effects. though i often only use 500 mg/d (occasionally 250 mg/d), i find patients still get a huge effect from the med. and, by the way, given some issues with metformin tolerance (mostly GI), i often leave younger people on 500 mg once or twice a day, with really good effect (ie, i rarely crank it up to the 1000 bid dosage, since my sense from the not-so-great literature, and my experience, is that 500-1000 mg total per day gives about 75-85% of the efficacy of the maximal dose)

The FDA is revising its warnings about the risks of metformin in those with chronic kidney disease (CKD) -- see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494829.htm , or http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf​ for more info), "requiring manufacturers to revise labeling of metformin-containing drugs to indicate that these products may be safely used in patients with mild to moderate renal impairment". although i have sent out many blogs on metformin, i think it is such an important drug that i am sending out this as yet another one. the new FDA labeling recommendations:

--before starting metformin, check eGFR
--metformin is contraindicated in patients with an eGFR <30
--starting metformin in those with eGFR 30-45 is NOT recommended
--obtain eGFR at least annually, more frequently if increased risk of renal dysfunction (eg, elderly)
--if a patient is on metformin and the eGFR falls to below 45, assess the benefits and risks of continuing treatment [not further defined..]. discontinue metformin if eGFR falls to <30
--discontinue metformin at time, or before, an iodinated contrast imaging procedure in patients with eGFR 30-60, in those with a history of liver disease, alcoholism, or heart failure; and in those getting intra-arterial iodinated contrast. re-evaluate eGFR 48 hours after the procedure and restart metformin if renal function is stable. 

so, a few comments:
--it's about time.....   See a few of my many blogs below on metformin, which highlight its incredible importance in diabetics, its current use in the US in those with CKD despite prior strict precautions, its general use in Europe where regulatory agencies suggest using it with decreasing doses depending on the degree of CKD, and even a blog which refers to its effects on the microbiome (and suggesting that these effects may be extremely important in metformin's mechanism of action). 
--one concern with the above is that they suggest following eGFR more closely in the elderly.  this is difficult, since (at least in our lab), eGFR is not reported in those >70: “eGFR values may not be accurate on patients greater than 70 years of age and are not calculated". my approach is to continue with metformin in the elderly (even those in their 90s) if their creatinine seems "reasonable" -- not easy to quantitate, but if their creatinine is below 1.5 or so, and throwing in some gestalt about their likely muscle mass...  But, bottom line, i have been doing this for years on a pretty large patient base and without any adverse effects. though i often only use 500 mg/d (occasionally 250 mg/d), i find patients still get a huge effect from the med. and, by the way, given some issues with metformin tolerance (mostly GI), i often leave younger people on 500 mg once or twice a day, with really good effect (ie, i rarely crank it up to the 1000 bid dosage, since my sense from the not-so-great literature, and my experience, is that 500-1000 mg total per day gives about 75-85% of the efficacy of the maximal dose)

http://gmodestmedblogs.blogspot.com/2015/01/metformin-in-renal-failure.html is a more systematic review of metformin use in those with less severe CKD, suggesting an algorithm for metformin dose adjustment

http://gmodestmedblogs.blogspot.com/2015/06/metformin-ckd-and-death.html ​ which looked at 813 metformin users with severe CKD (creatinine >6 mg/dL) who did NOT have increased mortality if the dose of metformin was low (<= 500 mg/d)

http://gmodestmedblogs.blogspot.com/2014/10/heart-failure-microbiome.html  looked at the effect of red meat on the microbiome (increasing TMAO levels, which are strongly pro-atherogenic) and also highlighting that metformin induces positive changes in the microbiome which decrease insulin resistance

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more